S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   305.51 (-1.05%)
AAPL   156.43 (-1.17%)
MSFT   272.99 (-1.23%)
META   199.55 (-1.62%)
GOOGL   100.84 (-1.58%)
AMZN   96.66 (-1.41%)
TSLA   187.21 (-2.40%)
NVDA   262.00 (-1.25%)
NIO   9.16 (+2.58%)
BABA   97.99 (+13.78%)
AMD   93.85 (-2.86%)
T   18.77 (-0.53%)
F   11.56 (+0.35%)
MU   58.77 (-1.71%)
CGC   1.82 (-3.46%)
GE   92.76 (-0.59%)
DIS   94.82 (-0.84%)
AMC   5.35 (+17.58%)
PYPL   72.20 (-1.50%)
PFE   39.90 (-0.80%)
NFLX   323.10 (-1.39%)
S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   305.51 (-1.05%)
AAPL   156.43 (-1.17%)
MSFT   272.99 (-1.23%)
META   199.55 (-1.62%)
GOOGL   100.84 (-1.58%)
AMZN   96.66 (-1.41%)
TSLA   187.21 (-2.40%)
NVDA   262.00 (-1.25%)
NIO   9.16 (+2.58%)
BABA   97.99 (+13.78%)
AMD   93.85 (-2.86%)
T   18.77 (-0.53%)
F   11.56 (+0.35%)
MU   58.77 (-1.71%)
CGC   1.82 (-3.46%)
GE   92.76 (-0.59%)
DIS   94.82 (-0.84%)
AMC   5.35 (+17.58%)
PYPL   72.20 (-1.50%)
PFE   39.90 (-0.80%)
NFLX   323.10 (-1.39%)
S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   305.51 (-1.05%)
AAPL   156.43 (-1.17%)
MSFT   272.99 (-1.23%)
META   199.55 (-1.62%)
GOOGL   100.84 (-1.58%)
AMZN   96.66 (-1.41%)
TSLA   187.21 (-2.40%)
NVDA   262.00 (-1.25%)
NIO   9.16 (+2.58%)
BABA   97.99 (+13.78%)
AMD   93.85 (-2.86%)
T   18.77 (-0.53%)
F   11.56 (+0.35%)
MU   58.77 (-1.71%)
CGC   1.82 (-3.46%)
GE   92.76 (-0.59%)
DIS   94.82 (-0.84%)
AMC   5.35 (+17.58%)
PYPL   72.20 (-1.50%)
PFE   39.90 (-0.80%)
NFLX   323.10 (-1.39%)
S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   305.51 (-1.05%)
AAPL   156.43 (-1.17%)
MSFT   272.99 (-1.23%)
META   199.55 (-1.62%)
GOOGL   100.84 (-1.58%)
AMZN   96.66 (-1.41%)
TSLA   187.21 (-2.40%)
NVDA   262.00 (-1.25%)
NIO   9.16 (+2.58%)
BABA   97.99 (+13.78%)
AMD   93.85 (-2.86%)
T   18.77 (-0.53%)
F   11.56 (+0.35%)
MU   58.77 (-1.71%)
CGC   1.82 (-3.46%)
GE   92.76 (-0.59%)
DIS   94.82 (-0.84%)
AMC   5.35 (+17.58%)
PYPL   72.20 (-1.50%)
PFE   39.90 (-0.80%)
NFLX   323.10 (-1.39%)
NASDAQ:LIFE

aTyr Pharma - LIFE Stock Forecast, Price & News

$2.15
+0.18 (+9.14%)
(As of 03/28/2023 02:39 PM ET)
Add
Compare
Today's Range
$1.95
$2.20
50-Day Range
$1.88
$2.49
52-Week Range
$1.82
$5.97
Volume
658,613 shs
Average Volume
268,140 shs
Market Capitalization
$114.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

aTyr Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
790.5% Upside
$19.25 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.25mentions of aTyr Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3,696 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.09) to ($0.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

70th out of 1,002 stocks

Biological Products, Except Diagnostic Industry

12th out of 166 stocks


LIFE stock logo

About aTyr Pharma (NASDAQ:LIFE) Stock

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Stock News Headlines

Biden’s Big Lie…
Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. pixel
aTyr Pharma's Earnings: A Preview
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
aTyr Pharma to Present at Upcoming Investor Conferences
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Company Calendar

Last Earnings
8/09/2021
Today
3/28/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
49
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$19.25
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+610.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-45,340,000.00
Pretax Margin
-436.58%

Debt

Sales & Book Value

Annual Sales
$10.39 million
Book Value
$2.46 per share

Miscellaneous

Free Float
50,844,000
Market Cap
$104.73 million
Optionable
Optionable
Beta
1.23

Social Links


Key Executives

  • Sanjay S. ShuklaSanjay S. Shukla
    President, Chief Executive Officer & Director
  • Jill M. BroadfootJill M. Broadfoot
    Chief Financial Officer
  • Leslie Nangle
    Vice President-Research
  • Andrew B. Cubitt
    Vice President-External Scientific Alliances
  • Peter Villiger
    Vice President-Corporate Development













LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIFE shares.
View LIFE analyst ratings
or view top-rated stocks.

What is aTyr Pharma's stock price forecast for 2023?

5 equities research analysts have issued 12-month price objectives for aTyr Pharma's stock. Their LIFE share price forecasts range from $9.00 to $35.00. On average, they expect the company's stock price to reach $19.25 in the next twelve months. This suggests a possible upside of 877.2% from the stock's current price.
View analysts price targets for LIFE
or view top-rated stocks among Wall Street analysts.

How have LIFE shares performed in 2023?

aTyr Pharma's stock was trading at $2.19 at the beginning of the year. Since then, LIFE stock has decreased by 10.0% and is now trading at $1.97.
View the best growth stocks for 2023 here
.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 240,900 shares, a decrease of 6.8% from the February 28th total of 258,500 shares. Based on an average trading volume of 249,600 shares, the short-interest ratio is presently 1.0 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our LIFE earnings forecast
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.13.

When did aTyr Pharma's stock split?

aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (4.75%), VR Adviser LLC (4.04%), Citigroup Inc. (1.50%), Dimensional Fund Advisors LP (0.69%), Renaissance Technologies LLC (0.57%) and Two Sigma Investments LP (0.56%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends
.

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $1.97.

How much money does aTyr Pharma make?

aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $104.73 million and generates $10.39 million in revenue each year. The biotechnology company earns $-45,340,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.

This page (NASDAQ:LIFE) was last updated on 3/28/2023 by MarketBeat.com Staff